News

Investigators explored the measurement properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) among patients with chronic skin disease.

The CRL notes that additional mechanistic and natural history data have not altered the previous review conclusions.

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

The novel oral NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor has indicated its efficacy and safety across 3 clinical trials.

The FDA has issued a CRL for selective cortisol modulator relacorilant, citing a need for more evidence of effectiveness.

The FDA has approved oral neurokinin-1 receptor antagonist tradipitant for the prevention of motion sickness, marking the first approval in decades.

From FDA decisions to late-phase trial readouts and updated practice guidelines, 2025 delivered clinically actionable insights across sleep conditions.

Catch up on the most impactful headlines in hormonal disorders from all of 2025 with our Year in Review.

C3G treatment advances in 2025 with FDA approvals of iptacopan and pegcetacoplan, offering disease-modifying options

In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.

The FDA grants breakthrough therapy designation for ulizacaltamine for the treatment of essential tremor.

In 2025, psychiatry saw major FDA approvals, novel treatments, and pivotal clinical updates that are transforming care for depression, ADHD, schizophrenia, and anxiety.

The gastroenterology year in review covers FDA approvals, IBD breakthroughs, IL-23 therapies, new guidelines, and advances in GI care.

Catch up on the most impactful headlines in HF from all of 2025 with our Year in Review.

IgA nephropathy advanced in 2025 with FDA approvals, positive phase 3 trials, and growing disease-modifying therapies

New CDC recommendations on hepatitis B vaccination raise concerns over increased infections and healthcare costs, complicating public health efforts.

Catch up on news headlines highlighted in the dermatology space by HCPLive in 2025 with this Year in Review.

Significant advancements in allergy treatments emerge in 2025, including 4 FDA approved treatments for hereditary angioedema.

The hepatology year in review highlights FDA approvals, MASH therapies, viral hepatitis advances, cholestatic disease shifts, and evolving clinical guidance.

Catch up on the most impactful headlines in cardiology from all of 2025 with our Year in Review.

Clinicians across specialties explain how health misinformation is reshaping patient decisions, delaying care, and undermining trust.

Potent synthetic opioids are being disguised in everyday products—from THC vapes to counterfeit pills—putting teens at unseen, lethal risk.

The FDA has approved small-molecule pyruvate kinase R activator mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia.

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.

With the FDA approval of oral semaglutide, Garvey weighs safety, oversight, and the future direction of GLP-1 weight management therapy.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

Garvey reflects on the recent FDA approval of oral semaglutide (Wegovy) as the first GLP-1 pill for weight loss.

The approval indicates narsoplimab as the first and only treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy.